<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) incidence and mortality are constantly decreasing, but <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> still remains the third most prevalent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and the third most common cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in both males and females in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Recent rapid declines in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> incidence rates have largely been attributed to increases in screening that can detect and remove precancerous <z:mpath ids='MPATH_491'>polyps</z:mpath>, and the decrease in <z:hpo ids='HP_0011420'>death</z:hpo> rates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> largely reflects improvements in early detection, treatment and the understanding of molecular/genetic basis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>One of the important molecular/genetic findings is the presence of microsatellite instability (MSI) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Many studies have shown the importance of MSI testing in diagnosing <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> and predicting prognosis and response to chemotherapeutic agents in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Increased emphasis has been placed on the importance of MSI testing for <z:hpo ids='HP_0000001'>all</z:hpo> newly diagnosed individuals with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Both immunohistochemical staining (IHC) and polymerase chain reaction (PCR)-based MSI testing show high sensitivity and specificity in detecting MSI </plain></SENT>
<SENT sid="6" pm="."><plain>The current clinical guidelines and histopathology features are indicative of, but not reliable in diagnosing <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> with MSI </plain></SENT>
<SENT sid="7" pm="."><plain>Currently, there are evidences that universal testing for MSI starting with either IHC or PCR-based MSI testing is cost effective, sensitive, specific and is getting widely accepted </plain></SENT>
</text></document>